Document:

Exhibit 10.9

 Exhibit 10.9 

CONSULTING AGREEMENT 

This Consulting Agreement (this “Agreement”) is entered into as of September 1, 2008, between CoLucid Pharmaceuticals,
Inc., a corporation organized under the laws of Delaware (the “Company”), and LLH Associates, LLC, a limited liability company organized under the laws of New Jersey (the “Consulting Firm”). The Company wishes
to retain the Consulting Firm as an independent contractor to perform consulting services for the Company, and the Consulting Firm is willing to perform such services, on the terms set forth herein. The parties hereto have entered into a
Confidentiality Agreement, dated as of July 16, 2008 (the “Confidentiality Agreement”), in contemplation of the services referred to herein. 

Therefore, in consideration of the mutual promises set forth herein, the parties agree as follows: 

1. Consulting Services. The Consulting Firm shall cause the following services (the “Consulting Services”) to
be performed for the Company exclusively by Linda C. Hogan (the “Consultant”): 
 (a) The
Consultant shall not be an officer of the Company but shall have the title “Vice President, Business Development.” 

(b) The Consultant shall provide strategic advice to the Company with respect to its business plan, business development
strategies and other matters, as requested from time to time by the Board of Directors of the Company (the “Board”) and/or Chief Executive Officer. 

(c) Subject to the direction and authority of the Board and the Chief Executive Officer, the Consultant shall assist the
Chief Executive Officer in directing the Company’s efforts and activities with respect to merger and acquisition transactions involving any or all of the Company’s assets or the Company as a whole and with respect to partnering, strategic
alliance, collaboration, licensing, co-development and similar transactions involving any of the Company’s assets, compounds or programs. 
 The
Consultant shall devote, on average, two days per week to the Consulting Services. The parties acknowledge that the term “Services” as used in the Confidentiality Agreement refers to the Consulting Services. 

The Company shall indemnify and hold harmless the Consulting Firm and Consultant from any losses, expenses, claims or proceedings arising from
(i) any inaccurate or incomplete information provided by the Company to the Consultant or to any third party in connection with the Consulting Services; (ii) any action or inaction by the Consultant in connection with the Consulting
Services taken or not taken pursuant to the express direction of the Company; or (iii) any other matter in connection with the Consulting Services not involving negligence or more culpable conduct on the part of the Consultant. The foregoing
indemnity shall (x) survive the termination or expiration of this Agreement, (y) be in addition to any rights the Consulting Firm or Consultant may have at common law or otherwise, and (z) inure to the benefit of any successors,
assigns or personal representatives of the Consulting Firm and Consultant. 

 2. Compensation. In consideration for the Consulting Services and the covenants and
agreements of the Consulting Firm and Consultant pursuant to this Agreement and the Confidentiality Agreement, the Company shall pay to the Consulting Firm a consulting fee in the amount of $10,000 for each full month (pro rated for partial months)
during the term of this Agreement, and shall reimburse the Consulting Firm for its reasonable and properly documented out-of-pocket expenses in accordance with Company
policies. If the Company consummates a sale or partnering transaction with respect to any of the compounds developed from its stigmine platform, the Company will consider payment to the Consulting Firm of a discretionary cash bonus in an amount to
be determined by the Board, but the Company shall not be obligated to make any such payment. The Company shall grant to the Consulting Firm options (“Options”) to purchase shares of the Company’s common stock
(“Shares”) as follows: 
 (a) No later than the first meeting of the Board that is held after
October 1, 2008, the Company shall grant to the Consulting Firm Options to purchase 115,516 Shares, representing 0.33% of the number of Fully Diluted Shares as of the date hereof. For purposes hereof, the term “Fully Diluted
Shares” means, as of any time, the total number of Shares (i) issued and outstanding as of such time, (ii) reserved for issuance pursuant to stock option or equity incentive plans in effect as of such time, and (iii) issuable
upon conversion of any outstanding convertible securities or upon exercise of any outstanding warrants as of such time. 

(b) If the Company closes, during the term of this Agreement, the second tranche of its Series B financing, then the
Company shall evaluate a potential grant to the Consulting Firm of Options to purchase a number of Shares determined by the Board and, for purposes of such evaluation, the Board shall apply a methodology consistent with the methodology applied to
Vice Presidents of the Company, but the Company shall not be obligated to make any such grant. 
 (c) If the Company
consummates, during the term of this Agreement, a Major Transaction approved by the Board (and the stockholders, if required), then the Company shall grant to the Consulting Firm Options to purchase a number of Shares such that the Consulting
Firm’s Equity Holdings upon issuance of such Option constitute 1% of the number of Fully Diluted Shares at that time. For purposes hereof: 

(i) the term “Major Transaction” means either (x) a transaction as a result of which a third party
(excluding existing preferred stockholders and other parties who in the future provide venture capital or other financing to the Company) acquires majority voting control of the Company or acquires all or substantially all of the Company’s
assets and rights related to its migraine compound (COL-144) and related development program, or (y) a collaboration, strategic alliance or other partnering transaction pursuant to which the Company grants to a third party exclusive rights to
develop and commercialize the Company’s migraine compound (COL-144); and 

  
 -2- 

 (ii) the term “Consulting Firm’s Equity Holdings”
means, as of any time, the sum of (x) the number of Shares then owned by the Consulting Firm, plus (y) the number of Shares then subject to Options, whether or not vested, held by the Consulting Firm; provided that if any Shares or Options
have been transferred or disposed of by the Consulting Firm to the Consultant or otherwise, then those Shares or Options shall be treated as if they were still owned or held by the Consulting Firm. 

(d) Each of the Options: 

(i) shall be granted only if the Board determines, in its reasonable discretion, that the Consulting Firm and Consultant
have, from the date hereof through the date of grant, performed the Consulting Services in a satisfactory manner and complied with their obligations pursuant to this Agreement and the Confidentiality Agreement; 

(ii) shall be governed by and subject to the Company’s 2006 Equity Incentive Plan and an option agreement in form
and substance acceptable to the Company; 
 (iii) shall be “nonqualified” under applicable tax laws; 

(iv) shall have an exercise price per share equal to the fair market value of one Share as of the date of grant, as
determined by the Board; and 
 (v) shall vest as to 25% of the Shares on September 24, 2009, and as to the
remaining 75% of the Shares in equal monthly installments on the last day of each month, beginning October 31, 2009, over the following 36 months. 

3. Efforts and Devotion to Duties. The Consulting Firm shall devote its best efforts (and shall cause the Consultant to devote
her best efforts) to fulfilling its obligations hereunder and to do nothing that would harm the business or reputation of the Company. During the term of this Agreement, the Consulting Firm and Consultant shall be free to engage in other business
activities that do not adversely affect the Consulting Services, so long as such other activities are not in competition with the Company and are not inconsistent with this Agreement. The Consulting Firm and Consultant represent and warrant to the
Company that they have no existing obligation or commitment that conflicts with this Agreement or that would preclude them from performing their responsibilities hereunder, and they agree not to enter into any such conflicting obligation or
commitment. 
 4. Relationship and Authority. The Consulting Firm and Consultant shall be independent contractors (not
employees) with respect to the Company and shall have no authority to bind the Company or make commitments on its behalf. Except as stated in the 

  
 -3- 

 
preceding sentence, this Agreement shall not be deemed to create any employment, partnership, agency or other relationship between the Company, on the one hand, and the Consulting Firm or
Consultant, on the other hand. The Consulting Firm and Consultant shall have no right to participate in any employee benefit plan or arrangement of the Company. If the Consulting Firm and/or Consultant are reclassified by any governmental authority
as employees of the Company, they shall have no right to any Company benefits, except as required by law, even if they would be eligible therefor by the terms of the applicable benefit plans or arrangements. 

5. Term and Termination. The term of this Agreement shall continue indefinitely until such time as this Agreement is terminated
by either the Company or the Consulting Firm upon at least 10 days’ prior written notice to the other. Upon termination of this Agreement, the Company’s sole obligation to the Consulting Firm and Consultant shall be to pay any compensation
earned through the termination date pursuant to Section 2 above. Immediately following termination, the Consulting Firm and Consultant shall deliver to the Company all Company property in the possession or under the control of the Consulting
Firm or Consultant. All work product received, developed or created by the Consulting Firm and/or Consultant, alone or with others, during the performance of the Consulting Services (including, without limitation, all records, documents, notes, data
and other materials of any nature pertaining to the Consulting Services or reflecting confidential or proprietary information, trade secrets or other intellectual property of the Company) shall be deemed to be Company property; provided that the
materials described in Appendix A to the Confidentiality Agreement shall be deemed to be property of the Consulting Firm. 
 6.
Miscellaneous. 
 (a) No Assignment or Subcontracting without Consent. No party hereto may assign
any of its rights or obligations under this Agreement without the written consent of the other, except that the Company shall have the right to assign any or all of its rights or obligations hereunder to any of its affiliates or to any successor
company that acquires substantially all of the business operations to which the Consulting Services relate. Without limiting the generality of the foregoing, the Consulting Firm and Consultant shall not subcontract or delegate any of the services
hereunder without the prior written consent of the Company. 
 (b) Entire Agreement. This Agreement and the
Confidentiality Agreement together constitute the entire agreement, and supersede all prior agreements and understandings, written and oral, between the parties with respect to the Consulting Services. 

(c) Waivers. The failure by any party at any time to require performance of any provision hereof shall not affect
its right later to require such performance. No waiver in any one or more instances shall (except as otherwise stated therein) be deemed to be a further or continuing waiver of any such condition or breach in any other instances or a waiver of any
other condition or breach of any other term, covenant, representation or warranty. 

  
 -4- 

 (d) Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. 

(e) Governing Law. This Agreement shall be governed by and construed and enforced exclusively in accordance with
the laws of the State of Indiana, without regard to the conflicts of law principles thereof. 
 (f) Notices.
All notices and other communications in connection with this Agreement shall be in writing and shall be sent to the respective parties at the following addresses (or such other addresses as they may designate in accordance herewith) by registered or
certified mail, postage prepaid, or by express courier service, service fee prepaid, or by facsimile with a hard copy to follow via mail or express courier service in accordance with this paragraph. 

 

			
	To the Company:		 CoLucid Pharmaceuticals, Inc.
 2530 Meridian
Parkway
 Suite 300
 Durham, NC 27713

Attn: James F. White

		
	With copy to:		 Daniel L. Boeglin
 Baker & Daniels LLP

600 E. 96th Street, Suite 600
 Indianapolis, IN
46240

		
	To the Consulting Firm and/or the Consultant:		 LLH Associates, LLC
 11 Spring Hill Road

Annandale, NJ 08801
 Attn: Linda C. Hogan

 All notices shall be deemed given and received (i) if delivered by hand, immediately, (ii) if sent by
mail, three business days after posting, (iii) if delivered by express courier service, the next business day, or (iv) if sent by facsimile, at the time shown in the confirmed electronic receipt or on the first business day thereafter
if the notice is sent on a day other than a business day. 
 (g) Amendments. This Agreement may be amended only
by an instrument in writing executed by the parties sought to be bound thereby. 
 (h) Injunctive Relief. The
Consulting Firm and Consultant acknowledge that any violation or threatened violation of this Agreement will cause irreparable harm to the Company that is incapable of precise measurement and that, as a result, the Company will not have an adequate
remedy at law to redress such harm. Therefore, in addition to monetary damages and other remedies, the Company shall be entitled to injunctive relief, including temporary restraining orders and/or preliminary or permanent injunctions, without
posting bond. 

  
 -5- 

 As evidence of their acceptance of the terms set forth herein, the Company and the Consulting
Firm have executed this Agreement as of the date stated in the opening paragraph. 
  

							
	“COMPANY”
	
	COLUCID PHARMACEUTICALS, INC.
		
	By:		 /s/ J. F. White

			James F. White
			President and CEO
	
	“CONSULTING FIRM”
	
	LLH ASSOCIATES, LLC
		
	By:		 /s/ Linda C. Hogan

			Linda C. Hogan
			Its:				  

 By signing below, the Consultant joins into this Agreement for the purpose of acknowledging her
obligations and responsibilities hereunder. 
  

	
	 /s/ Linda C. Hogan

	Linda C. Hogan, Individually
	

  
 -6-Exhibit 10.13

 Exhibit 10.13 

COLUCID PHARMACEUTICALS, INC. 

INDEMNIFICATION AGREEMENT 

This Indemnification Agreement (this “Agreement”), dated as of
                    , is entered into by and between CoLucid Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and
                     (“Indemnitee”). 

RECITALS 
 A. The Company
and Indemnitee recognize the continued difficulty in obtaining liability insurance for the Company’s directors, officers, employees, stockholders, controlling persons, agents and fiduciaries, the significant increases in the cost of such
insurance and the general reductions in the coverage of such insurance. 
 B. The Company and Indemnitee further recognize the substantial
increase in corporate litigation in general, which subjects directors, officers, employees, controlling persons, stockholders, agents and fiduciaries to expensive litigation risks at the same time as the availability and coverage of liability
insurance has been severely limited. 
 C. Indemnitee does not regard the current protection available as adequate under the present
circumstances, and Indemnitee and other directors, officers, employees, stockholders, controlling persons, agents and fiduciaries of the Company may not be willing to serve in such capacities without additional protection. 

D. Indemnitee has certain rights to indemnification and/or insurance provided by
                     and its affiliated entities (collectively, the “Fund Indemnitors”), which Indemnitee and the Fund Indemnitors intend
to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided herein, with the Company’s acknowledgement and agreement to the foregoing being a material condition to Indemnitee’s willingness to serve on the
Board. 
 E. The Company (i) desires to attract and retain highly qualified individuals and entities, such as Indemnitee, to serve the
Company and, in part, in order to induce Indemnitee to be involved with the Company and (ii) wishes to provide for the indemnification and advancing of expenses to Indemnitee to the maximum extent permitted by law. 

F. In view of the considerations set forth above, the Company desires that Indemnitee be indemnified by the Company as set forth herein. 

NOW, THEREFORE, the Company and Indemnitee hereby agree as follows: 

1. Indemnification. 
 (a)
Indemnification of Expenses. The Company shall indemnify and hold harmless Indemnitee (including its respective directors, officers, partners, members, employees, agents and spouse, as applicable) and each person who controls Indemnitee or
who may be liable 

 
within the meaning of Section 15 of the Securities Act of 1933, as amended (the “Securities Act”), or Section 20 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) to the fullest extent permitted by law if Indemnitee was or is or becomes a party to or witness or other participant in, or is threatened to be made a party to or witness or other participant in, any threatened, pending or
completed action, suit, proceeding or alternative dispute resolution mechanism, or any hearing, inquiry or investigation that Indemnitee believes might lead to the institution of any such action, suit, proceeding or alternative dispute resolution
mechanism, whether civil, criminal, administrative, investigative or other (hereinafter a “Claim”) by reason of (or arising in part or in whole out of) any event or occurrence related to the fact that Indemnitee is or was or may be deemed
a director, officer, stockholder, employee, controlling person, agent or fiduciary of the Company, or any subsidiary of the Company, or is or was or may be deemed to be serving at the request of the Company as a director, officer, stockholder,
employee, controlling person, agent or fiduciary of another corporation, partnership, limited liability company, joint venture, trust or other enterprise, or by reason of any action or inaction on the part of Indemnitee while serving in such
capacity including, without limitation, any and all losses, claims, damages, expenses and liabilities, joint or several (including any investigation, legal and other expenses incurred in connection with, and any amount paid in settlement of, any
Claim asserted) under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise or which relate directly or indirectly to the registration, purchase, sale or ownership of any securities of
the Company or to any fiduciary obligation owed with respect thereto or as a direct or indirect result of any Claim made by any stockholder of the Company against Indemnitee and arising out of or related to any round of financing of the Company
(including but not limited to Claims regarding non-participation, or non-pro rata participation, in such round by such stockholder), or made by a third party against Indemnitee based on any misstatement or omission of a material fact by the Company
in violation of any duty of disclosure imposed on the Company by federal or state securities or common laws (hereinafter an “Indemnification Event”) against any and all expenses (including attorneys’ fees and all other costs, expenses
and obligations incurred in connection with investigating, defending a witness in or participating in (including on appeal), or preparing to defend, be a witness in or participate in, any such Claim), judgments, fines, penalties and amounts paid in
settlement (if, and only if, such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld) of such Claim and any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or
deemed receipt of any payments under this Agreement (collectively, hereinafter “Expenses”), including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses. Such payment of Expenses
shall be made by the Company as soon as practicable but in any event no later than ten (10) days after written demand by Indemnitee therefor is presented to the Company. 

(b) Reviewing Party. Notwithstanding the foregoing, (i) the obligations of the Company under Section 1(a) shall be subject to
the condition that the Reviewing Party (as described in Section 10(e) hereof) shall not have determined (in a written opinion, in any case in which the Independent Legal Counsel referred to in Section 1(e) hereof is involved) that
Indemnitee would not be permitted to be indemnified under applicable law, and (ii) Indemnitee acknowledges and agrees that the obligation of the Company to make an advance payment of Expenses to Indemnitee pursuant to Section 2(a) (an
“Expense Advance”) shall be subject to the condition that, if, when and to the extent that the Reviewing Party determines that Indemnitee would not be permitted to be so indemnified under applicable law, the Company shall be entitled

  
 -2- 

 
to be reimbursed by Indemnitee (who hereby agrees to reimburse the Company) for all such amounts theretofore paid; provided, however, that if Indemnitee has commenced or thereafter commences
legal proceedings in a court of competent jurisdiction to secure a determination that Indemnitee should be indemnified under applicable law, any determination made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under
applicable law shall not be binding and Indemnitee shall not be required to reimburse the Company for any Expense Advance until a final judicial determination is made with respect thereto (as to which all rights of appeal therefrom have been
exhausted or lapsed). Indemnitee’s obligation to reimburse the Company for any Expense Advance shall be unsecured and no interest shall be charged thereon. If there has not been a Change in Control (as defined in Section 10(c) hereof), the
Reviewing Party shall be selected by the Board of Directors, and if there has been such a Change in Control (other than a Change in Control which has been approved by a majority of the Company’s Board of Directors who were directors immediately
prior to such Change in Control), the Reviewing Party shall be the Independent Legal Counsel referred to in Section 1(e) hereof. If there has been no determination by the Reviewing Party or if the Reviewing Party determines that Indemnitee
substantively would not be permitted to be indemnified in whole or in part under applicable law, Indemnitee shall have the right to commence litigation seeking an initial determination by the court or challenging any such determination by the
Reviewing Party or any aspect thereof, including the legal or factual bases therefor, and the Company hereby consents to service of process and to appear in any such proceeding. Any determination by the Reviewing Party otherwise shall be conclusive
and binding on the Company and Indemnitee. 
 (c) Contribution. If the indemnification provided for in Section 1(a) above for
any reason is held by a court of competent jurisdiction to be unavailable to Indemnitee in respect of any losses, claims, damages, expenses or liabilities referred to therein, then the Company, in lieu of indemnifying Indemnitee thereunder, shall
contribute to the amount paid or payable by Indemnitee as a result of such losses, claims, damages, expenses or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and Indemnitee, or
(ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the
Company and Indemnitee in connection with the action or inaction which resulted in such losses, claims, damages, expenses or liabilities, as well as any other relevant equitable considerations. In connection with the registration of the
Company’s securities, the relative benefits received by the Company and Indemnitee shall be deemed to be in the same respective proportions that the net proceeds from the offering (before deducting expenses) received by the Company and
Indemnitee, in each case as set forth in the table on the cover page of the applicable prospectus, bear to the aggregate public offering price of the securities so offered. The relative fault of the Company and Indemnitee shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or Indemnitee and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

  
 -3- 

 The Company and Indemnitee agree that it would not be just and equitable if contribution pursuant
to this Section 1(c) were determined by pro rata or per capita allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding paragraph. In connection with
the registration of the Company’s securities, in no event shall Indemnitee be required to contribute any amount under this Section 1(c) in excess of the lesser of (i) that proportion of the total of such losses, claims, damages or
liabilities indemnified against equal to the proportion of the total securities sold under such registration statement which is being sold by Indemnitee or (ii) the proceeds received by Indemnitee from his sale of securities under such
registration statement. No person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not found guilty of such fraudulent
misrepresentation. 
 (d) Survival Regardless of Investigation. The indemnification and contribution provided for in this
Section 1 will remain in full force and effect regardless of any investigation made by or on behalf of Indemnitee or any officer, director, employee, agent or controlling person of the Indemnitee. 

(e) Change in Control. The Company agrees that if there is a Change in Control of the Company (other than a Change in Control which has
been approved by a majority of the Company’s Board of Directors who were directors immediately prior to such Change in Control) then, with respect to all matters thereafter arising concerning the rights of Indemnitee to payments of Expenses
under this Agreement or any other agreement or under the Company’s Certificate of Incorporation, as amended (the “Certificate”), or Bylaws as now or hereafter in effect, Independent Legal Counsel (as defined in Section 10(d)
hereof) shall be selected by Indemnitee and approved by the Company (which approval shall not be unreasonably withheld). Such counsel, among other things, shall render its written opinion to the Company and Indemnitee as to whether and to what
extent Indemnitee would be permitted to be indemnified under applicable law. The Company agrees to abide by such opinion and to pay the reasonable fees of the Independent Legal Counsel referred to above and to fully indemnify such counsel against
any and all expenses (including attorneys’ fees), claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

(f) Mandatory Payment of Expenses. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been
successful on the merits or otherwise, including, without limitation, the dismissal of an action without prejudice, in the defense of any Claim referred to in Section 1(a) hereof or in the defense of any claim, issue or matter therein,
Indemnitee shall be indemnified against all Expenses incurred by Indemnitee in connection herewith. 
 2. Expenses; Indemnification
Procedure. 
 (a) Advancement of Expenses. The Company shall advance all Expenses incurred by Indemnitee. The advances to be made
hereunder shall be paid by the Company to Indemnitee as soon as practicable but in any event no later than fifteen (15) days after written demand by Indemnitee therefor to the Company. 

  
 -4- 

 (b) Notice/Cooperation by Indemnitee. Indemnitee shall give the Company notice as soon as
practicable of any Claim made against Indemnitee for which indemnification will or could be sought under this Agreement. Notice to the Company shall be directed to the Chief Executive Officer of the Company at the address shown on the signature page
of this Agreement (or such other address as the Company shall designate in writing to Indemnitee). 
 (c) No Presumptions; Burden of
Proof. For purposes of this Agreement, the termination of any Claim by judgment, order, settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create a presumption that
Indemnitee did not meet any particular standard of conduct or have any particular belief or that a court has determined that indemnification is not permitted by applicable law. In addition, neither the failure of the Reviewing Party to have made a
determination as to whether Indemnitee has met any particular standard of conduct or had any particular belief, nor an actual determination by the Reviewing Party that Indemnitee has not met such standard of conduct or did not have such belief,
prior to the commencement of legal proceedings by Indemnitee to secure a judicial determination that Indemnitee should be indemnified under applicable law, shall be a defense to Indemnitee’s claim or create a presumption that Indemnitee has not
met any particular standard of conduct or did not have any particular belief. In connection with any determination by the Reviewing Party or otherwise as to whether Indemnitee is entitled to be indemnified hereunder, the burden of proof shall be on
the Company to establish that Indemnitee is not so entitled. 
 (d) Notice to Insurers. If, at the time of the receipt by the Company
of a notice of a Claim pursuant to Section 2(b) hereof, the Company has liability insurance in effect which may cover such Claim, the Company shall give prompt written notice of the commencement of such Claim to the insurers in accordance with
the procedures set forth in each of the policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Claim in accordance with the terms
of such policies. 
 (e) Selection of Counsel. In the event the Company shall be obligated hereunder to pay the Expenses of any
Claim, the Company shall be entitled to assume the defense of such Claim, with counsel reasonably approved by Indemnitee, upon the delivery to Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such
counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same Claim; provided that,
(i) Indemnitee shall have the right to employ Indemnitee’s counsel in any such Claim at Indemnitee’s expense; (ii) Indemnitee shall have the right to employ his own counsel in connection with any such proceeding, at the expense
of the Company, if such counsel serves in a review, observer, advice and counseling capacity and does not otherwise materially control or participate in the defense of such proceeding; and (iii) if (A) the employment of counsel by
Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and Indemnitee in the conduct of any such defense, or (C) the Company shall
not continue to retain such counsel to defend such Claim, then the fees and expenses of Indemnitee’s counsel shall be at the expense of the Company. 

  
 -5- 

 3. Additional Indemnification Rights; Nonexclusively. 

(a) Scope. The Company hereby agrees to indemnify Indemnitee to the fullest extent permitted by law, even if such indemnification is
not specifically authorized by the other provisions of this Agreement or any other agreement, the Certificate, the Company’s Bylaws or by statute. In the event of any change after the date of this Agreement in any applicable law, statute or
rule which expands the right of a Delaware corporation to indemnify a member of its Board of Directors or an officer, stockholder, employee, controlling person, agent or fiduciary, it is the intent of the parties hereto that Indemnitee shall enjoy
by this Agreement the greater benefits afforded by such change. In the event of any change in any applicable law, statute or rule which narrows the right of a Delaware corporation to indemnify a member of its Board of Directors or an officer,
employee, agent or fiduciary, such change, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement, shall have no effect on this Agreement or the parties’ rights and obligations hereunder except as set
forth in Section 8(a) hereof. 
 (b) Nonexclusivity. Notwithstanding anything in this Agreement, the indemnification provided by
this Agreement shall be in addition to any rights to which Indemnitee may be entitled under the Certificate, the Company’s Bylaws, any agreement, any vote of stockholders or disinterested directors, the laws of the State of Delaware, or
otherwise. Notwithstanding anything in this Agreement, the indemnification provided under this Agreement shall continue as to Indemnitee for any action Indemnitee took or did not take while serving in an indemnified capacity even though Indemnitee
may have ceased to serve in such capacity and such indemnification shall inure to the benefit of Indemnitee from and after Indemnitee’s first day of service as a director with the Company or affiliation with a director from and after the date
such director commences services as a director with the Company. 
 (c) Affiliated Entities. Notwithstanding anything to the contrary
contained in this Agreement, the Company hereby agrees to indemnify and hold harmless any entity, including, without limitation, a corporation, partnership, joint venture, trust or other enterprise, affiliated with the Indemnitee that also was or is
a stockholder of the Company (an “Affiliated Entity”), to the fullest extent permitted by law, against all Expenses of any threatened, pending or completed Claim (i) arising primarily by reason of the fact that an Affiliated Entity
has the ability to appoint or elect Indemnitee to the Board of Directors, (ii) for any acts, omissions or transactions by the Indemnitee while acting in the capacity of a director, officer, controlling person, stockholder, employee or other
agent of the Company or (iii) that is otherwise related to the fact that the Indemnitee was or is serving as, a director, officer, controlling person, stockholder, employee or other agent of the Company. The terms of this Agreement as they
relate to procedures for indemnification of Indemnitee shall apply to any such indemnification of an Affiliated Entity. The Company and Indemnitee agree that each Affiliated Entity is an intended third party beneficiary of this Agreement. 

4. No Duplication of Payments. 

(a) The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance provided
by the Fund Indemnitors. The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to 

  
 -6- 

 
Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary),
(ii) that it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and
as required by the terms of this Agreement and the Certificate or Bylaws (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and (iii) that it irrevocably
waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment
by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to
the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of this Section 4(a).

 (b) Except as provided in Section 4(a) above, the Company shall not be liable under this Agreement to make any payment in connection
with any Claim made against Indemnitee to the extent Indemnitee has otherwise actually received payment (under any insurance policy, Certificate, Bylaws or otherwise) of the amounts otherwise indemnifiable hereunder. 

5. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for any
portion of Losses or Expenses incurred in connection with any Claim, but not, however, for all of the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such Losses or Expenses to which Indemnitee is
entitled. 
 6. Mutual Acknowledgement. The Company and Indemnitee acknowledge that in certain instances, Federal law or applicable
public policy may prohibit the Company from indemnifying its directors, officers, employees, controlling persons, agents or fiduciaries under this Agreement or otherwise. 

7. Liability Insurance. To the extent the Company maintains liability insurance applicable to directors, officers, employees, control
persons, agents or fiduciaries, Indemnitee shall be covered by such policies in such a manner as to provide Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company’s directors, if the Indemnitee is a
director, or of the Company’s officers, if such Indemnitee is not a director of the Company but is an officer; or of the Company’s key employees, controlling persons, agents or fiduciaries, if such Indemnitee is not an officer or director
but is a key employee, agent, control person, or fiduciary as the case may be. 
 8. Exceptions. Any other provision herein to the
contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement: 
 (a) Claims Under
Section 16(b). To indemnify Indemnitee for expenses and the payment of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of the Exchange Act or any similar successor statute; or 

(b) Unlawful Indemnification. To indemnify Indemnitee if a final decision by a court having jurisdiction in the matter shall determine that
such indemnification is not lawful. 

  
 -7- 

 9. Period of Limitations. No legal action shall be brought and no cause of action shall be
asserted by or in the right of the Company against Indemnitee, Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the expiration of five (5) years from the date of accrual of such cause of action, and
any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such five (5) year period; provided, however, that if any shorter period of limitations is
otherwise applicable to any such cause of action, such shorter period shall govern. 
 10. Construction of Certain Phrases. 

(a) For purposes of this Agreement, references to the “Company” shall include, in addition to the resulting corporation, any
constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, employees, agents or
fiduciaries, so that if Indemnitee is or was or may be deemed a director, officer, employee, agent, control person, or fiduciary of such constituent corporation, or is or was or may be deemed to be serving at the request of such constituent
corporation as a director, officer, employee, control person, agent or fiduciary of another corporation, partnership, joint venture, employee benefit plan, trust or other enterprise, Indemnitee shall stand in the same position under the provisions
of this Agreement with respect to the resulting or surviving corporation as Indemnitee would have with respect to such constituent corporation if its separate existence had continued. 

(b) For purposes of this Agreement, references to “other enterprises” shall include employee benefit plans; references to
“fines” shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to “serving at the request of the Company” shall include any service as a director, officer, employee, agent
or fiduciary of the Company which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee benefit plan, its participants or its beneficiaries; and if Indemnitee acted in good faith
and in a manner Indemnitee reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner “not opposed to the best interests of the Company”
as referred to in this Agreement. 
 (c) For purposes of this Agreement a “Change in Control” shall be deemed to have occurred if
(i) any “person” (as such term is used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act), other than a trustee or other fiduciary holding securities under an employee benefit plan of the Company or a corporation owned directly or
indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company, (A) who is or becomes the beneficial owner, directly or indirectly, of securities of the Company

  
 -8- 

 
representing 20% or more of the combined voting power of the Company’s then outstanding Voting Securities, increases his beneficial ownership of such securities by 5% or more over the
percentage so owned by such person, or (B) becomes the “beneficial owner” (as defined in Rule 13d-3 under said Exchange Act), directly or indirectly, of securities of the Company representing more than 30% of the total voting power
represented by the Company’s then outstanding Voting Securities, (ii) during any period of two consecutive years, individuals who at the beginning of such period constitute the Board of Directors of the Company and any new director whose
election by the Board of Directors or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the period
or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof, or (iii) the stockholders of the Company approve a merger or consolidation of the Company with any other corporation
other than a merger or consolidation which would result in the Voting Securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities of the
surviving entity) at least two-thirds (2/3) of the total voting power represented by the Voting Securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Company
approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of (in one transaction or a series of transactions) all or substantially all of the Company’s assets. 

(d) For purposes of this Agreement, “Independent Legal Counsel” shall mean an attorney or firm of attorneys, selected in accordance
with the provisions of Section 1(e) hereof, who shall not have otherwise performed services for the Company or Indemnitee within the last three (3) years (other than with respect to matters concerning the right of Indemnitee under this
Agreement, or of other indemnitees under similar indemnity agreements). 
 (e) For purposes of this Agreement, a “Reviewing Party”
shall mean any appropriate person or body consisting of a member or members of the Company’s Board of Directors or any other person or body appointed by the Board of Directors who is not a party to the particular Claim for which Indemnitee is
seeking indemnification, or Independent Legal Counsel. 
 (f) For purposes of this Agreement, “Voting Securities” shall mean any
securities of the Company that vote generally in the election of directors. 
 11. Counterparts. This Agreement may be executed in
two or more counterparts, each of which shall constitute an original. 
 12. Binding Effect; Successors and Assigns. This Agreement
shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors, assigns, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially
all of the business and/or assets of the Company, spouses, heirs, and personal and legal representatives. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all,
substantially all, or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to 

  
 -9- 

 
perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. This Agreement shall continue in effect with
respect to Claims relating to Indemnifiable Events regardless of whether Indemnitee continues to serve as a director, officer, employee, agent, controlling person, or fiduciary of the Company or of any other enterprise, including subsidiaries of the
Company, at the Company’s request. 
 13. Attorneys’ Fees. In the event that any action is instituted by Indemnitee under
this Agreement or under any liability insurance policies maintained by the Company to enforce or interpret any of the terms hereof or thereof, Indemnitee shall be entitled to be paid all Expenses incurred by Indemnitee with respect to such action,
regardless of whether Indemnitee is ultimately successful in such action, and shall be entitled to the advancement of Expenses with respect to such action, unless, as a part of such action, a court of competent jurisdiction over such action
determines that each of the material assertions made by Indemnitee as a basis for such action was not made in good faith or was frivolous. In the event of an action instituted by or in the name of the Company under this Agreement to enforce or
interpret any of the terms of this Agreement, Indemnitee shall be entitled to be paid all Expenses incurred by Indemnitee in defense of such action (including costs and expenses incurred with respect to Indemnitee counterclaims and cross-claims made
in such action), and shall be entitled to the advancement of Expenses with respect to such action. 
 14. Notice. All notices and
other communications required or permitted hereunder shall be in writing, shall be effective when given, and shall in any event be deemed to be given (a) five (5) days after deposit with the U.S. Postal Service or other applicable postal
service, if delivered by first class mail, postage prepaid certified, (b) upon delivery, if delivered by hand, (c) one business day after the business day of deposit with Federal Express or similar overnight courier, freight prepaid, or
(d) one day after the business day of delivery by facsimile transmission, if deliverable by facsimile transmission, with copy by first class mail, postage prepaid, and shall be addressed if to Indemnitee, at Indemnitee’s address as set
forth beneath Indemnitee’s signature to this Agreement and if to the Company at the address of its principal corporate offices (attention: Secretary) or at such other address as such party may designate by ten (10) days’ advance
written notice to the other party hereto. 
 15. Severability. The provisions of this Agreement shall be severable in the event that
any of the provisions hereof (including any provision within a single section, paragraph or sentence) are held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable, and the remaining provisions shall remain enforceable
to the fullest extent permitted by law. Furthermore, to the fullest extent possible, the provisions of this Agreement (including, without limitations, each portion of this Agreement containing any provision held to be invalid, void or otherwise
unenforceable, that is not itself invalid, void or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable. 

16. Choice of Law. This Agreement shall be governed by and its provisions construed and enforced in accordance with the laws of the
State of Delaware, as applied to contracts between Delaware residents, entered into and to be performed entirely within the State of Delaware, without regard to the conflict of laws principles thereof. 

  
 -10- 

 17. Subrogation. Except as provided in Section 4(a) above, in the event of payment
under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to
enable the Company effectively to bring suit to enforce such rights. 
 18. Amendment and Termination. No amendment, modification,
termination or cancellation of this Agreement shall be effective unless it is in writing signed by the parties to be bound thereby. Notice of same shall be provided to all parties hereto. No waiver of any of the provisions of this Agreement shall be
deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 

19. Corporate Authority. The Board of Directors of the Company in accordance with Delaware law has approved the terms of this
Agreement. 
 [REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK] 

  
 -11- 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first set
forth above. 
  

			
	“COMPANY”
	
	COLUCID PHARMACEUTICALS, INC.
		
	By		  

			Thomas P. Mathers
			Chief Executive Officer
	
	Address:
	15 New England Executive Park
	Burlington, MA 01803
	
	“INDEMNITEE”
	
	  

			
	
	Address:
	
	
	

 [Signature Page to Indemnification Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]